Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates

MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. 

SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2a clinical trial in adults with newly diagnosed glioblastoma. 

Additional indications are being evaluated through: 
- Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide) 
- Phase 1 in Neuro-Endocrine Tumors (NET)
- Pilot Study in Pediatric High Grade Glioma, recurrent/relapsed Medulloblastoma and DIPG

MimiVax, Inc.

Org chart

Teams

Offices

MimiVax, Inc.

Org chart

Teams

Offices

Related companies